GlassScriptPhysician profile
Mahesh Bajaj
NPI 1649247537
$7,528.50
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $1,486 · 2021: $1,952 · 2022: $2,219 · 2023: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,574.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,488.75 | 2019-2023 | Trelegy Ellipta |
| Genzyme Corporation | $736.82 | 2019-2023 | |
| Csl Behring | $629.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $614.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.73 | 2020-2023 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $286.86 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $272.02 | 2019-2023 | Xembify |
| Amgen INC. | $266.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.35 | 2019-2022 | |
| Pharming Healthcare, INC. | $160.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $150.26 | 2021-2022 | |
| Optinose US, INC. | $135.17 | 2020-2022 | |
| Octapharma USA, INC. | $127.02 | 2019-2020 | |
| Kaleo, INC. | $102.62 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $99.33 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $87.16 | 2020-2021 | |
| Covis Pharma Gmbh | $63.16 | 2021-2022 | |
| Shire North American Group INC | $50.18 | 2019 | |
| Merck Sharp & Dohme LLC | $35.53 | 2021 | |
| Leo Pharma INC. | $26.25 | 2022 | |
| Biocryst US Sales Co., LLC | $19.59 | 2022 | |
| Aimmune Therapeutics, INC. | $18.84 | 2020 | |
| Alk-Abello, INC | $15.80 | 2019 | |
| Hikma Pharmaceuticals USA | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahesh Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.